Avalo Therapeutics

Avalo Therapeutics

  • Founded: 2011
  • Location: Rockville, MD
  • Employee range: 11 - 50
  • Clinical stage: Clin3 (fast track)
  • Therapy area: Leukocyte deficiency syndrome II (ODD)
  • Drug types: HEM, GEN, INF, LNG, GI, IMM
  • Lead product: AVTX-803
  • Product link: https://www.avalotx.com/pipeline
  • Funding: $15M stock Feb 2023; $31.5M stock Sep 2021; $36.4M stock Jan 2021



job board

Short description:

Small molecules for neuro / psychiatric disorders

Drug notes:

AVTX-002 Clin2 (fast track) COVID-19 ARDS, Clin2 (failed Jun 2023) non-eosinophilic asthma, Clin1 Crohn's; AVTX-008 RD/Clin0 immunoregulatory disorders

Long description:

Avalo Therapeutics is creating treatments for patients with unmet clinical needs in immunology and rare genetic diseases. At the core of Avalo’s therapeutics is immune regulation by targeting the LIGHT-signaling network. LIGHT is a newly recognised cytokine with inflammatory actions in the lung, gut and skin, encoded by the TNFSF14 gene. The LIGHT immune regulatory network is suggested to be dysregulated and a disease-driving mechanism in autoimmune and inflammatory reactions. By reducing signaling through the LIGHT-signaling network, Avalo hopes to moderate immune dysregulation. Avalo’s pipeline includes various biologics focused on dysregulated inflammation via the LIGHT-signaling network with several in clinical stages.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com